THOMASVILLE — Archbold Urology is committed to offering patients in the region access to the most advanced treatments for urologic conditions that affect many of its neighbors.

Clinically known as benign prostatic hyperplasia (BPH), enlarged prostate is a non‑cancerous condition that affects roughly half of men ages 51 to 60, with incidence increasing ...

FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

Roquefort Therapeutics is acquiring exclusive worldwide rights to a clinical-stage tumour inhibitor for £32m in an all-paper ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate cancer, according to an industry press release. As Healio previously reported, ...

The U.S. Food and Drug Administration on Friday approved a new ​formulation of Lantheus Holdings' prostate cancer imaging agent, aimed at improving ‌scanning access through increased production ...

Oxybutynin significantly reduced hot flash frequency and severity compared with placebo among men with prostate cancer ...

Investigators sought to determine the effect of “Smart PSA” guidelines on screening behavior and biopsy outcomes among Black men.

I am in relatively good health for an 82-year-old male. For the past six years, I have been having trouble with an overactive ...

I am in relatively good health for an 82-year-old male. For the past six years, I have been having trouble with an overactive bladder. I need to ...

Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with ...